The hazard ratio (HR) for tumor recurrence in patients with BRAFV600E and TERT promoter mutations was 6.74 (95% CI: 2.17–20.91, p = 0.001) (Table 3, upper), which remained significant after adjustment for patient age, sex, and lymph node metastasis (HR: 4.17, 95% CI: 1.06–17.7, p = 0.048) (Table 3, upper). Here, TERT is linked to metastatic malignant neoplasm in the lymph nodes.